A
Abacus Medicine
Sustainability Report and Carbon Intensity Rankings
Is Abacus Medicine doing their part?
Their DitchCarbon score is 53
Abacus Medicine has a DitchCarbon Score of 53 out of 100, indicating a moderate level of sustainability in their operations. This score reflects the company’s carbon intensity, which is a measure of the greenhouse gases emitted relative to the value they generate. A higher score would suggest a lower carbon intensity and a stronger commitment to reducing emissions.
This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.
Industry emissions intensity
Very low
Low
Medium
High
Very high
Abacus Medicine is part of the industrial manufacturing sector, which has a very low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.
Location emissions intensity
Very low
Low
Medium
High
Very high
Abacus Medicine operates in Denmark, a country with a very low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint through the national energy mix.
Unlock 30+ emissions data points on Abacus Medicine
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
Unlock 30+ emissions data points on Abacus Medicine
Get the emissions intelligence you need, no surveys required.
– Historical Scope 1, 2 and 3 emissions
– Coverage of all industries, product level data
– Emissions forecasting, assurances
11.71%
...this company is doing 11.71% better in emissions than the industry average.
Abacus Medicine, founded in 2004 and headquartered in Copenhagen, operates within the industrial manufacturing sector, specifically focusing on the distribution of pharmaceuticals. The company specializes in parallel distribution, offering original European pharmaceuticals at reduced costs to pharmacies and hospitals across Europe, including Germany, Sweden, and Denmark. With over 2000 marketing licenses, Abacus Medicine plays a crucial role in the healthcare sector by enhancing the affordability of medicine for businesses and consumers alike.
emission intelligence's platform recommendations for Abacus Medicine
Abacus Medicine should undertake a thorough inventory of all Scope 1 emissions sources to identify and mitigate direct greenhouse gas emissions.
Good news, Abacus Medicine has set solid SBTi commitments
Abacus Medicine has committed to significantly reducing their greenhouse gas emissions across their operations, aligning with the ambitious 1.5°C warming limit. This involves tackling emissions from both direct operations and indirect energy sources, known as scope 1 and scope 2 emissions.
Participating
Claim this profile
Are you associate with this company?
Help us improve our data and claim this profile.
Our methodology
Read about our emission calculation methodologies, and what the DitchCarbon Score means.
Looking for a specific company?
Search our company directory or contact us for custom data requests.